

In re application of:

Serial No.: 09/442,256

Filed: November 17, 1999

For:

**ANTI-CANCER PHARMACEUTICAL COMPOSITIONS AND METHODS**

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

Transmitted herewith is an Amendment and Response Under 37 C.F.R. §1.111 in the above-identified application.

- ☒ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- ☐ Petition for Extension of Time
- ☐ No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	* 37	MINUS	** 53	= 0
INDEP	* 4	MINUS	*** 3	= 1
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM				

SMALL ENTITY	
RATE	ADDIT. FEE
x 9 =	\$0
x 40 =	\$ 40.00
+135 =	\$
TOTAL ADDIT. FEE	\$ 40.00

OTHER THAN A SMALL ENTITY	
RATE	ADDIT. FEE
x18 =	\$ 0
x80 =	\$ 0
+270 =	\$ 0
TOTAL ADDIT. FEE	\$ 0

\* If the entry in Col.1 is less than the entry in Col.2, write "0" in Col.3.  
\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.  
\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.  
The "Highest Number Previously Paid For" (Total or Independent) is the number found from the equivalent box in Col.1 of a prior amendment the number of claims originally filed.

- ☐ Please charge my Deposit Account No. 11-0855 in the amount of \$\_\_\_\_. A duplicate copy of this sheet is attached.
- ☒ A check in the amount of \$40 is attached.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 11-0855. A duplicate copy of this sheet is attached.
- ☒ Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

Kristin D. Mallatt  
Kristin D. Mallatt, Reg. No. 46,895

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Tesfaye Zerihun  
Yigzaw



SERIAL NO.: 09/442,256 GROUP ART UNIT: 1651

FILED: November 17, 1999 EXAMINER: H. Lilling

FOR: ANTI-CANCER PHARMACEUTICAL COMPOSITIONS AND METHODS

Attorney Docket No.:38179/190315

I hereby certify that this document, together with any document referred to as enclosed or attached, is being transmitted to the Assistant Commissioner for Patents, Washington, D.C. 20231, via first-class mail, on this 3rd day of November, 2000.

Assistant Commissioner for  
Patents  
Washington, D.C. 20231

DATE: November 3, 2000

AMENDMENT AND RESPONSE UNDER 37 CFR §1.111

Sir:

Responsive to the Office action dated August 10, 2000, setting a shortened statutory period for response expiring on November 10, 2000, Applicant respectfully submits the following remarks in connection with the above-identified application.

IN THE CLAIMS

Please cancel claims 2, 3, 7, 10, 11, 15-21, 23, 27-28, 30-31, 33-35, 37, 41-53

without prejudice or disclaimer to the subject matter thereof.

11/08/2000 SDENBOB1 00000015 09442256

01 FC:202

40.00 OP